Loading…
Genprex, Inc. is projected to decline to $0.5069 by 2027, a -9% move from its current price of $0.5599. GNPX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.5279 | $0.56 | $0.594 | +0.01% |
| Jul 14 | $0.5152 | $0.5601 | $0.6088 | +0.03% |
| Jul 15 | $0.5057 | $0.5601 | $0.6204 | +0.04% |
| Jul 16 | $0.4979 | $0.5602 | $0.6304 | +0.06% |
| Jul 17 | $0.4911 | $0.5603 | $0.6393 | +0.07% |
| Jul 18 | $0.485 | $0.5604 | $0.6475 | +0.08% |
| Jul 19 | $0.4795 | $0.5604 | $0.6551 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4795 | $0.5604 | $0.6551 | +0.10% |
| Week 2 | $0.4499 | $0.561 | $0.6995 | +0.19% |
| Week 3 | $0.4285 | $0.5615 | $0.7358 | +0.29% |
| Week 4 | $0.4114 | $0.5621 | $0.768 | +0.39% |
| Week 5 | $0.3969 | $0.5626 | $0.7976 | +0.49% |
| Week 6 | $0.3843 | $0.5632 | $0.8254 | +0.59% |
| Week 7 | $0.373 | $0.5637 | $0.8519 | +0.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. Its oncology program uses a systemic, non-viral Oncoprex Delivery System that encapsulates gene-expressing plasmids with lipid-based nanoparticles in a lipoplex form.
The lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Incorporated in 2009 and based in Austin, Texas, Genprex also pursues diabetes gene therapy programs, including GPX-002 that delivers Pdx1 and MafA to the pancreas using an AAV vector. The company also engages in research partnerships with major medical centers to study biomarkers and response predictors for Reqorsa Gene Therapy.
Genprex, Inc. trades in the Healthcare sector. Its current price is $0.5639 with a market cap of $6.16M, and it sits at rank 5254 by market capitalization. The stock’s price outlook is captured by a year-by-year forecast that shows near-term volatility but potential longer-term upside, including a 2030 average of $0.6118 and a 2050 average of $1.45.
A major floor 57.5% below — a decisive break under it would weaken the trend.
The nearest floor, 22.1% below — buyers have tended to step in here.
The nearest ceiling, 42.0% above — a clean break opens room to run.
A major ceiling 269.7% above — clearing it would confirm fresh momentum.
Key GNPX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GNPX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5784 | Sell | $0.5637 | Sell |
| MA 10 | $0.5521 | Buy | $0.5589 | Buy |
| MA 20 | $0.5419 | Buy | $0.5775 | Sell |
| MA 50 | $0.6986 | Sell | $0.7701 | Sell |
| MA 100 | $1.19 | Sell | $1.48 | Sell |
| MA 200 | $3.28 | Sell | $7.12 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.75 | Neutral |
| Stoch RSI (14) | 68.16 | Neutral |
| CCI (20) | 24.88 | Neutral |
| Williams %R (14) | -40.67 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 7.49 | Buy |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 59.33 | Neutral |
| TRIX (15) | -1.36 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 53.81 | Neutral |
| Momentum (10) | 0.09 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 0.57 | Sell |
| ADX (14) | 28.87 | Sell |
| ATR (14) | 0.03 | Info |
Near term, market sentiment is NEUTRAL with RSI(14) at 40. The stock trades below the SMA50 of $0.7133 and well below the SMA200 of $3.39, signaling limited momentum in the very near term. Support is at $0.436 and resistance at $0.795, guiding potential moves within a 30-day range of $0.3733 to $0.8518.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.436 | $0.5599 | $0.7992 | 0% | Neutral | |
| $0.3678 | $0.5069 | $0.7553 | -9% | Neutral | |
| $0.3041 | $0.4454 | $0.7073 | -20% | Bearish | |
| $0.3073 | $0.4741 | $0.7904 | -15% | Bearish | |
| $0.3763 | $0.6086 | $1.06 | +9% | Neutral | |
| $0.4406 | $0.7448 | $1.34 | +33% | Bullish | |
| $0.3962 | $0.6987 | $1.29 | +25% | Bullish | |
| $0.3681 | $0.676 | $1.29 | +21% | Bullish | |
| $0.3443 | $0.6577 | $1.28 | +17% | Neutral | |
| $0.2956 | $0.587 | $1.17 | +5% | Neutral | |
| $0.3876 | $0.8613 | $1.89 | +54% | Bullish | |
| $0.6396 | $1.42 | $3.27 | +154% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.436 | $0.5599 | $0.6505 | +0.00% |
| August 2026 | $0.4393 | $0.5321 | $0.6711 | -4.97% |
| September 2026 | $0.4616 | $0.567 | $0.7303 | +6.57% |
| October 2026 | $0.4531 | $0.5635 | $0.7384 | -0.63% |
| November 2026 | $0.4406 | $0.5537 | $0.7361 | -1.73% |
| December 2026 | $0.4676 | $0.5933 | $0.7992 | +7.15% |
Click any year to see its month-by-month GNPX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GNPX could reach as high as $0.7992, with a base case around $0.5599 and support toward $0.436 — roughly 0% from $0.5599. Price action looks broadly range-bound.
Expect GNPX to range from $0.3678 to $0.7553 through 2027. The $0.5069 average target implies a -9% move from current prices. That is -9% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The GNPX price prediction for 2028 points to an average of $0.4454 (low $0.3041, high $0.7073) — a potential decline of -20% on today's $0.5599. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2029, GNPX is projected to trade between $0.3073 and $0.7904, averaging $0.4741 — a potential decline of -15% from today's $0.5599. That is up +6% on the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
Genprex, Inc.'s 2030 outlook centres on $0.6086, within a $0.3763 to $1.06 range. That is up +28% on the projected 2029 average. That marks a +9% change versus current levels. Price action looks broadly range-bound.
By 2031, GNPX could reach as high as $1.34, with a base case around $0.7448 and support toward $0.4406 — roughly +33% from $0.5599. Buyers look set to stay in control over this stretch.
Expect GNPX to range from $0.3962 to $1.29 through 2032. The $0.6987 average target implies a +25% move from current prices. That is -6% versus the projected 2031 average. Momentum favours further upside here.
The GNPX price prediction for 2033 points to an average of $0.676 (low $0.3681, high $1.29) — a potential gain of +21% on today's $0.5599. Buyers look set to stay in control over this stretch.
In 2034, GNPX is projected to trade between $0.3443 and $1.28, averaging $0.6577 — a potential gain of +17% from today's $0.5599. That is -3% versus the projected 2033 average. Price action looks broadly range-bound.
Genprex, Inc.'s 2035 outlook centres on $0.587, within a $0.2956 to $1.17 range. That is -11% versus the projected 2034 average. That marks a +5% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, GNPX could reach as high as $1.89, with a base case around $0.8613 and support toward $0.3876 — roughly +54% from $0.5599. Momentum favours further upside here.
Expect GNPX to range from $0.6396 to $3.27 through 2050. The $1.42 average target implies a +154% move from current prices. That is up +65% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GNPX today (≈ 1,786.03322 GNPX) could be worth
$2,538.45
+$1,538.45 (+154%) by 2050 · US Dollar
Based on the average projected GNPX price of $1.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GNPXwould be worth at today's price.
$1,000 invested in GNPX on Jul 10, 2025 (≈ 68.728521 GNPX) would be worth
$38.48
-$961.52 (-96.2%) today · 0.04× · US Dollar
Based on a GNPX entry price of $14.55 vs. today's $0.5599.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.576 | $972.05 | -2.8% |
| 1 month ago | $0.636 | $880.35 | -12.0% |
| 3 months ago | $1.15 | $486.87 | -51.3% |
| 6 months ago | $2.6 | $215.35 | -78.5% |
| 1 year ago | $14.55 | $38.48 | -96.2% |
| All time (5.0y) ago | $6,080 | $0.09 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GNPX forecast.
Our base-case forecast reaches $1.10 around 2050.
Implied market cap at $1.10: $12.02M
The multi-year forecast shows a mixed path through 2026–2029, with 2026 min $0.436, avg $0.5639, max $0.8122 and ROI 0%; 2027 avg $0.5069 with ROI -10.1%; 2028 avg $0.4457 with ROI -21%; 2029 avg $0.4838 with ROI -14.2%. By 2030 the forecast turns more constructive: avg $0.6118 with ROI 8.5%, min $0.3781, max $1.06. From 2031 onward, sentiment shifts to bullish, with 2031 avg $0.7485 ROI 32.7%, 2032 avg $0.7075 ROI 25.5%, 2033 avg $0.6768 ROI 20%, 2034 avg $0.6632 ROI 17.6%, and 2035 avg $0.595 ROI 5.5%.
The longer horizon shows continued upside, with 2040 avg $0.8666 ROI 53.7% and 2050 avg $1.45 ROI 156.4% (max $3.33). The forecast also notes higher volatility, with annualized volatility at 100%.
Tap a question to reveal the answer.
2030 forecast shows an average price of $0.6118 with a range from $0.3781 to $1.06 and an estimated ROI of 8.5%. The sentiment is NEUTRAL.
Near-term signals are NEUTRAL with negative ROIs in 2027 (-10.1%), 2028 (-21%), and 2029 (-14.2%). Longer term, there are bullish indicators from 2031 onward, with 2031 ROI 32.7% and 2040 ROI 53.7%, and a 2050 ROI of 156.4%, suggesting potential upside alongside notable risk.
Yes. The 2030 max forecast is $1.06, and the 2050 max forecast is $3.33, indicating achievable upside at those horizons.
From 2026 to 2030, the averages are 2026 $0.5639, 2027 $0.5069, 2028 $0.4457, 2029 $0.4838, and 2030 $0.6118, with corresponding ROIs of 0%, -10.1%, -21%, -14.2%, and 8.5%.
The current price is $0.5639 and the market cap is $6.16M.
Genprex, Inc. Community Discussion
0Share your Genprex, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.